Search bioRxiv⌕ Search

bioRxiv · 10.64898/2025.12.16.694607

Inconsistent Subthalamic Beta Expression in the Local Field Potential amid In- and Anti-Phasic Neuronal Bursts.

Abstract

BackgroundElevated beta (12-32 Hz) activity in the local field potential (LFP) of the subthalamic nucleus (STN) is a hallmark of Parkinsons disease and closely tied to synchronized spiking. Albeit the biomarkers prevalence has not been independently and reliably assessed, it is employed to guide deep brain stimulation (DBS) lead implantation. Likewise, beta is under investigation to inform DBS programming and adaptive DBS. This study assesses the applicability of these efforts by quantifying the biomarkers prevalence and investigating its relationship to synchronized beta-bursting neurons. MethodsSTN LFP and spiking activity of n = 156 patients with Parkinsons disease from six DBS centers recorded via microelectrodes was examined. Spectral peaks in the LFPs were classified and the absence of artifacts confirmed. The distribution of phase angles between beta LFP and spiking of individual beta-bursting neurons were explored. FindingsBilateral beta LFP expression was observed in 47{middle dot}25% of patients, and in 65{middle dot}59% of hemispheres. LFP-synchronized neuronal spiking clustered in two-thirds of neurons at a primary and in one-third at a secondary LFP phase (182{middle dot}84{degrees} phase shifted). This applied on the group level and for individual patients across different DBS centers. InterpretationBeta-informed approaches mandate reliable biomarker expression, a requirement not met by slightly more than half of herein investigated patients. This is particularly troublesome for intraoperative guidance wherein the cause of biomarker absence, including DBS lead misplacement or a balanced ratio of phasic and antiphasic spiking neurons, cannot be determined, decreasing insight and increasing doubt. Although beta LFPs remain a valuable biomarker, routine clinical practice should not rely on beta alone; instead, multiple biomarkers (i.e. beta-gamma coupling, finely tuned gamma and/or cortico-cortical beta-band coupling) should be evaluated simultaneously to increase robustness. FundingMaximilian Scherer received funding from the Alexander von Humboldt-Foundation. Thomas Koeglsperger has been supported by the Munich Clinician Scientist Program.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Scherer, M., Wiedemann, N., Boetzel, K., Loehle, M., Kriesen, T., Cantre, D., Mehrkens, J. H., Reese, R., Koeglsperger, T.. 2025-12-19. Inconsistent Subthalamic Beta Expression in the Local Field Potential amid In- and Anti-Phasic Neuronal Bursts.. https://doi.org/10.64898/2025.12.16.694607

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience↗

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience↗

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience↗